MK-8776 (SCH 900776)

MK-8776 (SCH 900776) is a selective Chk1 inhibitor with IC50 of 3 nM in a cell-free assay. It shows 500-fold selectivity against Chk2. Phase 2.

MK-8776 (SCH 900776) Chemical Structure

MK-8776 (SCH 900776) Chemical Structure

CAS: 891494-63-6

Selleck's MK-8776 (SCH 900776) has been cited by 67 publications

Purity & Quality Control

Batch: Purity: 99.98%
99.98

MK-8776 (SCH 900776) Related Products

Signaling Pathway

Choose Selective Chk Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
U251 Growth Inhibition Assay 200/2000 nM 24 h decreases the IC50 of Gemcitabine 24359526
HCT115 Growth Inhibition Assay 200/2000 nM 24 h decreases the IC50 of Gemcitabine 24359526
SW620 Growth Inhibition Assay 200/2000 nM 24 h decreases the IC50 of Gemcitabine 24359526
IGROV-1 Growth Inhibition Assay 200/2000 nM 24 h decreases the IC50 of Gemcitabine 24359526
HCT116 Growth Inhibition Assay 200/2000 nM 24 h decreases the IC50 of Gemcitabine 24359526
MCF10A Growth Inhibition Assay 200/2000 nM 24 h decreases the IC50 of Gemcitabine 24359526
MiaPaCa-2 Growth Inhibition Assay 200/2000 nM 24 h decreases the IC50 of Gemcitabine 24359526
MDA-MB-231 Growth Inhibition Assay 200/2000 nM 24 h decreases the IC50 of Gemcitabine 24359526
HCC2998 Growth Inhibition Assay 200/2000 nM 24 h decreases the IC50 of Gemcitabine 24359526
U87 Growth Inhibition Assay 200/2000 nM 24 h decreases the IC50 of Gemcitabine 24359526
MDA-MB-435 Growth Inhibition Assay 200/2000 nM 24 h decreases the IC50 of Gemcitabine 24359526
SNB19 Growth Inhibition Assay 200/2000 nM 24 h decreases the IC50 of Gemcitabine 24359526
U20S Growth Inhibition Assay 200/2000 nM 24 h decreases the IC50 of Gemcitabine 24359526
A498 Growth Inhibition Assay 200/2000 nM 24 h decreases the IC50 of Gemcitabine 24359526
TK10 Growth Inhibition Assay 200/2000 nM 24 h decreases the IC50 of Gemcitabine 24359526
AsPC-1 Growth Inhibition Assay 200/2000 nM 24 h decreases the IC50 of Gemcitabine 24359526
H23 Growth Inhibition Assay 500 nM 24 h DMSO enhances the chemosensitization to PMX 24113549
H1437 Growth Inhibition Assay 500 nM 24 h DMSO enhances the chemosensitization to PMX 24113549
H1993 Growth Inhibition Assay 500 nM 24 h DMSO enhances the chemosensitization to PMX 24113549
H1299 Growth Inhibition Assay 500 nM 24 h DMSO enhances the chemosensitization to PMX 24113549
AsPC-1 Growth Inhibition Assay 10-1000 nM 24-48h enhances the chemosensitization to gemcitabine 23804422
MiaPaCa-2 Growth Inhibition Assay 10-1000 nM 24-48h enhances the chemosensitization to gemcitabine 23804422
BxPC-3 Growth Inhibition Assay 10-1000 nM 24-48h enhances the chemosensitization to gemcitabine 23804422
SKOV3 Growth Inhibition Assay 0.3 µM 8 d sensitizes the cell lines to gemcitabine  23548269
OVCAR-8 Growth Inhibition Assay 0.3 µM 8 d sensitizes the cell lines to gemcitabine  23548269
MV-4-11 Apoptosis Assay 100-700 nM 48 h induces apoptosis dose dependently 23536721
U937 Apoptosis Assay 100-700 nM 48 h induces apoptosis dose dependently 23536721
MOLM-13  Apoptosis Assay 100-700 nM 48 h induces apoptosis dose dependently 23536721
A2058  Cell Viability Assay 37.5-300 nM 72 h DMSO reduces the MK-1775 EC50 by 5-fold to an average of 45 nM 23148684
H2009 Cell Viability Assay 500 nM 72 h DMSO results in G1/S-phase accumulation combined with MK-1775 23148684
Su.86.86 Cell Viability Assay 500 nM 72 h DMSO results in G1/S-phase accumulation combined with MK-1775 23148684
HRE Cell Viability Assay 500 nM 72 h DMSO results in G1/S-phase accumulation combined with MK-1775 23148684
HMEC Cell Viability Assay 500 nM 72 h DMSO results in G1/S-phase accumulation combined with MK-1775 23148684
U2OS  Function Assay 2 µM 0-24 h induces phosphorylation of Chk1 at serine 345 at both concentrations as early as 2 h after administration 22937147
U2OS  Growth Inhibition Assay 0-10 µM 24/48 h inhibits cell growth dose dependently 22937147
U937 Function Assay 100-500 nM 4 h  decreases the cytarabine-induced Chk1 autophosphorylation at Ser296 and prevents Cdc25A downregulation 22869869
U937 Function Assay 100 nM 4 h  reverses the cytarabine-induced inhibition of 3H-thymidine incorporation into DNA 22869869
U937 Function Assay 100-500 nM 4 h  induces increased phosphorylation of H2AX 22869869
HL-60 Apoptosis Assay 30/100/300 nM 24 h DMSO enhances cytarabine-induced apoptosis 22869869
ML-1 Apoptosis Assay 25/50/100 nM 24 h DMSO enhances cytarabine-induced apoptosis 22869869
HCT116 Function Assay 1 µM 24 h abrogates of cell cycle arrest  22510560
U2OS Function Assay 1 µM 24 h abrogates of cell cycle arrest  22510560
Sf9 Function assay Inhibition of recombinant CDK2/Cyclin A expressed in insect Sf9 cells assessed as inhibition of [33P]-ATP incorporation into biotinylated histone H1 after 1 hr by liquid scintillation counting, IC50 = 0.16 μM. 21094607
Click to View More Cell Line Experimental Data

Biological Activity

Description MK-8776 (SCH 900776) is a selective Chk1 inhibitor with IC50 of 3 nM in a cell-free assay. It shows 500-fold selectivity against Chk2. Phase 2.
Targets
Chk1 [1]
(Cell-free assay)
CDK2 [1]
(Cell-free assay)
3 nM 0.16 μM
In vitro
In vitro

SCH 900776 is a less potent inhibitor of Chk2 and CDK2 with IC50 of 1.5 μM and 0.16 μM, respectively. SCH 900776 shows no significant inhibition of cytochrome P450 human liver microsomal isoforms 1A2, 2C9, 2C19, 2D6, and 3A4. SCH 900776 induces a dose-dependent loss of DNA replication capability 24 hours after hydroxyurea exposure. SCH 900776 enhances the γ-H2AX response of hydroxyurea, 5-fluoruracil, and cytarabine. In combination with an antimetabolite, SCH 900776 induces accumulation of γ-H2AX within 2 hours, indicative of replication fork collapse and double stranded DNA breaks. Additionally, SCH 900776 suppresses accumulation of the Chk1 pS296 autophosphorylation in a dose-dependent manner. Exposure of proliferating WS1 cells to SCH 900776 is associated with rapid, dose-dependent accumulation of Chk1 pS345, indicating that cycling populations of normal cells induce Chk1 pS345 following exposure to SCH 900776 as part of a futile cycle, perhaps driven by AT-family kinases and DNA-PK.[1]

Kinase Assay Chk1 SPA assay
An in vitro assay utilizing recombinant His-Chk1 expressed in the baculovirus expression system as an enzyme source and biotinylated peptide based upon CDC25C as substrate. His-Chk1 is diluted to 32 nM in kinase buffer containing 50 mM Tris pH 8.0, 10 mM MgCl2, and 1 mM DTT. CDC25C (CDC25 Ser216 C-term biotinylated peptide) peptide is diluted to 1.93 μM in kinase buffer. For each kinase reaction, 20 μL of 32 nM Chk1 enzyme solution and 20 μL of 1.926 μM CDC25C are mixed and combined with 10 μL of SCH 900776 diluted in 10% DMSO, making final reaction concentrations of 6.2 nM Chk1, 385 nM CDC25C and 1% DMSO after addition of start solution. The reaction is started by addition of 50 μL of start solution consisting of 2 μM ATP and 0.2 μCi of 33P-ATP, making a final reaction concentration of 1 μM ATP, with 0.2 μCi of 33P-ATP per reaction. Kinase reactions run for 2 hours at room temperature and are stopped by the addition of 100 μL of stop solution consisting of 2 M NaCl, 1% H3PO4, and 5 mg/mL Streptavidin-coated SPA beads. SPA beads are captured using a 96-well GF/B filter plate and a Filtermate universal harvester. Beads are washed twice with 2 M NaCl and twice with 2 M NaCl with 1% phosphoric acid. Signal is then assayed using a TopCount 96-well liquid scintillation counter. Dose-response curves are generated from duplicate 8 point serial dilutions of SCH 900776. IC50 values are derived by nonlinear regression analysis.
Cell Research Cell lines mESCs
Concentrations 10 μM
Incubation Time 1 h
Method

Cells were treated with inhibitors or vehicle for 1 hour

Experimental Result Images Methods Biomarkers Images PMID
Western blot Cyclin E / pY15-CDK / γH2AX p-chk1(ser345) / CDC25A 26595527
In Vivo
In vivo

Administered 30 minutes after gemcitabine, 4 mg/kg SCH 900776 is sufficient to induce the γ-H2AX biomarker while 8 mg/kg leads to enhanced tumor pharmacodynamic and regression responses relative to gemcitabine or SCH 900776 alone. Dose escalation of SCH 900776 (16 mg/kg and 32 mg/kg) induces incremental improvements in tumor response. Importantly, doses of SCH 900776 associate with robust biomarker activation and improved tumor response are not associated with enhanced toxicity of gemcitabine on hematological parameters in BALB/c mice. [1]

Animal Research Animal Models Female nude mice injected subcutaneously with A2780 or MiaPaCa2 cells
Dosages ~50 mg/kg
Administration Administered intraperitoneally
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00779584 Completed
Hodgkin Disease|Lymphoma Non-Hodgkin|Neoplasms
Merck Sharp & Dohme LLC
October 17 2008 Phase 1

Chemical Information & Solubility

Molecular Weight 376.25 Formula

C15H18BrN7

CAS No. 891494-63-6 SDF Download MK-8776 (SCH 900776) SDF
Smiles CN1C=C(C=N1)C2=C3N=C(C(=C(N3N=C2)N)Br)C4CCCNC4
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 75 mg/mL ( (199.33 mM); Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
I would like to know whether your product S2735 is the optically pure R enantiomer or whether it is a racemic mix.

Answer:
Our S2735 MK-8776 (SCH 900776) is R enantiomer.

Tags: buy MK-8776|MK-8776 ic50|MK-8776 price|MK-8776 cost|MK-8776 solubility dmso|MK-8776 purchase|MK-8776 manufacturer|MK-8776 research buy|MK-8776 order|MK-8776 mouse|MK-8776 chemical structure|MK-8776 mw|MK-8776 molecular weight|MK-8776 datasheet|MK-8776 supplier|MK-8776 in vitro|MK-8776 cell line|MK-8776 concentration|MK-8776 nmr|MK-8776 in vivo|MK-8776 clinical trial|MK-8776 inhibitor|MK-8776 Cell Cycle inhibitor